ProCE Banner Activity

Cases in CLL: Frontline Therapy Selection and Clinical Trial Considerations for a Patient With Multiple Comorbidities

Clinical Thought
In this commentary, an expert faculty discusses key considerations and shared decision-making in choosing treatment for a patient with CLL.

Released: July 07, 2022

Expiration: July 06, 2023

Share

Faculty

Lindsey Roeker

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Eli Lilly

Janssen Biotech

Pharmacyclics an AbbVie Company

TG Therapeutics

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Lindsey Roeker, MD: consultant: AbbVie, Ascentage, AstraZeneca, BeiGene, Janssen, Loxo, Pfizer, Pharmacyclics, TG Therapeutics; research funding (to institution): Aptose, Loxo, Pfizer; minority ownership interest: Abbott.